{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:56Z","timestamp":1786120256326,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/gme.0b013e3182214f5a","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T15:34:55Z","timestamp":1317742495000},"page":"67-74","source":"Crossref","is-referenced-by-count":5,"title":["Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate"],"prefix":"10.1097","volume":"19","author":[{"given":"Santiago","family":"Palacios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Neyro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Villero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Ca\u00f1ada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Teresa","family":"Caloto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Nocea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210211","first-page":"295","article-title":"Clinical use of biological markers of bone turnover in osteoporosis in French.","volume":"29","author":"Bergmann","year":"2008","journal-title":"Rev Med Brux"},{"key":"R3-13-20210211","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ejrad.2008.04.063","article-title":"Clinical and therapeutic aspects of osteoporosis.","volume":"71","author":"Compston","year":"2009","journal-title":"Eur J Radiol"},{"key":"R4-13-20210211","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/bmb\/ldn017","article-title":"Update on the treatment of post-menopausal osteoporosis.","volume":"86","author":"Cole","year":"2008","journal-title":"Br Med Bull"},{"key":"R5-13-20210211","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density.","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-13-20210211","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/sim.984","article-title":"A method to assess the proportion of treatment effect explained by a surrogate endpoint.","volume":"20","author":"Li","year":"2001","journal-title":"Stat Med"},{"key":"R12-13-20210211","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bone.2003.12.022","article-title":"Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy.","volume":"34","author":"Delmas","year":"2004","journal-title":"Bone"},{"key":"R14-13-20210211","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.maturitas.2003.12.006","article-title":"Postmenopausal osteoporosis and alendronate.","volume":"48","author":"Perez-Lopez","year":"2004","journal-title":"Maturitas"},{"key":"R15-13-20210211","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00044011-200626020-00002","article-title":"Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS-international.","volume":"26","author":"Reid","year":"2006","journal-title":"Clin Drug Investig"},{"key":"R16-13-20210211","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00198-004-1770-7","article-title":"Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.","volume":"16","author":"Chapurlat","year":"2005","journal-title":"Osteoporos Int"},{"key":"R17-13-20210211","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11914-005-0018-6","article-title":"Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction.","volume":"3","author":"Miller","year":"2005","journal-title":"Curr Osteoporos Rep"},{"key":"R18-13-20210211","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11914-009-0014-3","article-title":"Bone markers in osteoporosis.","volume":"7","author":"Garnero","year":"2009","journal-title":"Curr Osteoporos Rep"},{"key":"R19-13-20210211","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women.","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"key":"R21-13-20210211","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00198-006-0218-7","article-title":"Potential for bone turnover markers to cost-effectively identify and select post-menopuasal osteopenic women at high risk of fracture for bisphosphonate therapy.","volume":"18","author":"Schousboe","year":"2007","journal-title":"Osteoporos Int"},{"key":"R22-13-20210211","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jcp.2007.048868","article-title":"The cell biology of bone metabolism.","volume":"61","author":"Datta","year":"2008","journal-title":"J Clin Pathol"},{"key":"R23-13-20210211","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"key":"R24-13-20210211","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00774-004-0590-3","article-title":"Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with one-year response of lumbar bone mineral density to alendronate in Japanese postmenopausal women with osteoporosis.","volume":"23","author":"Iwamoto","year":"2005","journal-title":"J Bone Miner Metab"},{"key":"R27-13-20210211","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"R28-13-20210211","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3349\/ymj.2009.50.4.474","article-title":"Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.","volume":"50","author":"Iwamoto","year":"2009","journal-title":"Yonsei Med J"},{"key":"R30-13-20210211","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.","volume":"19","author":"Seibel","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R32-13-20210211","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate therapy.","volume":"79","author":"Garnero","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-13-20210211","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"R37-13-20210211","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/PL00004183","article-title":"Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.","volume":"11","author":"Fink","year":"2000","journal-title":"Osteoporosis Int"},{"key":"R40-13-20210211","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/TCRM.S6901","article-title":"Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures.","volume":"5","author":"Iwamoto","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"R42-13-20210211","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1359\/jbmr.1999.14.4.602","article-title":"Monitoring alendronate therapy for osteoporosis.","volume":"14","author":"Braga","year":"1999","journal-title":"J Bone Miner Res"},{"key":"R43-13-20210211","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00774-003-0438-2","article-title":"Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.","volume":"21","author":"Chailurkit","year":"2003","journal-title":"J Bone Miner Metab"},{"key":"R45-13-20210211","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00774-006-0739-3","article-title":"Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.","volume":"25","author":"Takada","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"R50-13-20210211","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(03)00112-1","article-title":"Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal.","volume":"33","author":"Bagger","year":"2003","journal-title":"Bone"},{"key":"R53-13-20210211","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","article-title":"Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.","volume":"114","author":"McClung","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R54-13-20210211","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1359\/JBMR.050609","article-title":"Identification of osteopenic women at high risk of fracture: the OFELY study.","volume":"20","author":"Sornay-Rendu","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R57-13-20210211","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1210\/jc.2002-021654","article-title":"An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men.","volume":"88","author":"Drake","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R58-13-20210211","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00198-007-0379-z","article-title":"Prediction of bone loss using biochemical markers of bone turnover.","volume":"18","author":"Lenora","year":"2007","journal-title":"Osteoporos Int"},{"key":"R59-13-20210211","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s002239900226","article-title":"Prediction of bone loss rate in healthy postmenopausal women.","volume":"60","author":"Reginster","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"R60-13-20210211","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1359\/jbmr.1999.14.9.1614","article-title":"Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study.","volume":"14","author":"Garnero","year":"1999","journal-title":"J Bone Miner Res"},{"key":"R61-13-20210211","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1359\/jbmr.2000.15.7.1398","article-title":"Biochemical markers as predictors of rates of bone loss after menopause.","volume":"15","author":"Rogers","year":"2000","journal-title":"J Bone Miner Res"},{"key":"R62-13-20210211","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bone.2006.09.026","article-title":"Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. the OFELY study.","volume":"40","author":"Garnero","year":"2007","journal-title":"Bone"},{"key":"R63-13-20210211","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res"},{"key":"R64-13-20210211","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s002239900235","article-title":"Specific changes of urinary excretion of cross-linked N-telopeptides of type I collagen in pre- and postmenopausal women: correlation with other markers of bone turnover.","volume":"60","author":"Gorai","year":"1997","journal-title":"Calcif Tissue Int"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00042192-201201000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:21:28Z","timestamp":1786047688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042192-201201000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e3182214f5a","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}